Ascletis Announces Investigational Compound ASC47 for Obesity Treatment
Ascletis has announced its investigational compound, ASC47, a promising candidate for obesity treatment that promotes weight loss while preserving muscle mass. In preclinical evaluations, combining ASC47 with tirzepatide resulted in a 38.1% reduction in body weight in obese mice, significantly surpassing the 23.1% decrease observed with semaglutide alone.
Preclinical Study Details
The study involved obese mice subjected to various treatments over 14 to 28 days. Notably, the combination of a low dose of ASC47 with tirzepatide nearly restored the mice's body composition to that of healthy, non-obese counterparts. The muscle mass percentage in these mice was similar to that of non-obese controls, indicating healthy weight loss without muscle depletion. Monotherapy with tirzepatide alone did not achieve this restoration.
Company Statements and Future Plans
"These preclinical results support the therapeutic potential of ASC47 as part of an effective obesity treatment strategy," stated Jinzi Jason Wu, Ph.D., Founder, Chairman, and CEO of Ascletis. He added that upcoming topline ...